Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby, Roger A., Louise Firth, and Edmund J. Lewis. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby, Roger A., Louise Firth, and Edmund J. Lewis
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In a community-based pharmaceutical care services program for 194 participants in 2001, days of sick time decreased at each interval (each year for 1-5 years) for one employer, with estimated…  
  • New and emerging technologies have made it easier for people with diabetes to manage their disease. Improved technology came in the form of a continuous glucose monitor, first approved by…  
  • Participants in a diabetes self-management education program for Medicaid recipients, consisting of a 60 minute initial individual assessment of needs, followed by 12 hours of group education on nutrition and…  
  • 150 drugs are in development for diabetes. Diabetes affects 12.2 million Americans age 60 and older.  
  • Every additional dollar spent on screening and treating diabetic eye disease in type 2 diabetics on insulin has produced health gains valued at $36.